Business
Medison Files Proxy Circular, Offers Knight Therapeutics Shareholders Truly Independent, Unconflicted Directors and Comprehensive Business Plan to Fix a Failing Knight
Medison Files Proxy Circular, Offers Knight Therapeutics Shareholders Truly Independent, U...
About this update from Knight Therapeutics, Inc.
[{"type":"text","content":"\n\n\n\nMedison Files Proxy Circular, Offers Knight Therapeutics Shareholders Truly Independent, Unconflicted Directors and Comprehensive Business Plan to Fix a Failing Knight\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nPETACH TIKVA, Israel, April 8, 2019\n\n\n\nKnight has failed to build a meaningful business or create long-term shareholder value, despite tremendous opportunities and unprecedented resourcesKnight share price has been floundering for over three years, significantly underperforming other pharmaceutical companiesCurrent Board and CEO are conflicted and entrenched, wasting corporate assets by attacking shareholders in an attempt to divert attention from the Company's poor execution and performanceMedison has developed a comprehensive plan to help Knight become a growing and profitable Canadian-based pharmaceutical company by 2025; new directors are needed to ensure the implementation of this planIn addition to current director Meir Jakobsohn, Medison has nominated five independent, experienced leaders from the pharmaceutical industry who will oversee Knight without conflict or compromiseMore information on the director nominees and Medison's comprehensive plan for Knight, including plans to return at least $100 million of excess capital to Knight shareholders in the form of a special dividend or share buyback, is available at www.NewDayForKnight.com PETACH TIKVA, Israel, April 8, 2019 /CNW/ - Medison Biotech (1995) Ltd. (\"Medison\"), which together with its affiliates owns more than 10.4 million shares or 7.3% of Knight Therapeutics Inc. (TSX:GUD) (\"Knight\" or the \"Company\"), today announced that it has filed a dissident information circular (\"Medison's Circular\") in connection with the Company's upcoming Annual and Special Meeting (the \"Meeting\") scheduled for May 7, 2019.\nMedison's Circular proposes a slate of six exceptional nominees for election as directors at the Meeting.  In addition to Medison's CEO, Meir Jakobsohn, a proven pharmaceutical leader who has served on the K...